Amphotericin B: Nursing Drug Guide, Nephrotoxicity & NCLEX Review
A potent IV antifungal reserved for progressive, life-threatening mycoses—where the nursing priority is preventing nephrotoxicity and catching infusion reactions before creatinine climbs or the patient decompensates.
Daily dose must not exceed 1.5 mg/kg. Verify product and mg/kg before every dose. Rapid IV infusion and saline dilution are dangerous. Monitor creatinine, potassium, and infusion-related vitals closely; stop and escalate for hemodynamic compromise or sharp renal decline.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Verify product and dose (never exceed 1.5 mg/kg/day), give only in 5% dextrose over 2–6 hours, pre-hydrate when ordered, and trend creatinine plus potassium—hold and escalate when renal function drops or infusion reactions become hemodynamically significant.
Most common brand names
Amphotericin B deoxycholate (conventional) is supplied for IV infusion; liposomal and lipid-complex formulations (e.g., AmBisome, Amphotec) are distinct products with different dosing and toxicity profiles—always verify the exact formulation on the vial and MAR.
Common names include Fungizone (amphotericin B deoxycholate) and liposomal amphotericin B (AmBisome). Institutional protocols and product formulations may vary.
Why we give it — Indications
Amphotericin B is a potent antifungal used when fungal disease is progressive and potentially life-threatening. It is not appropriate for noninvasive candidiasis in patients with normal neutrophil counts (e.g., oral thrush or vaginal candidiasis).
| Use | Detail |
|---|---|
| Life-threatening systemic mycoses | Including aspergillosis, cryptococcosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, blastomycosis, and selected zygomycoses when susceptible—per FDA-approved labeling. |
| Not for limited mucosal disease | Do not use for oral thrush, vaginal candidiasis, or esophageal candidiasis in patients with normal neutrophil counts—reserve for severe invasive infection. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Amphotericin B binds to ergosterol in fungal cell membranes, altering permeability and leading to cell death. Mammalian cell membranes also contain sterols, which contributes to its toxicity profile (renal, infusion-related, and electrolyte effects).
Dosing overview
Dosing is individualized by infection severity, cardiorenal function, and laboratory trends. Under no circumstances should total daily dose exceed 1.5 mg/kg. Verify product name and dose before every administration—especially when the ordered dose exceeds 1.5 mg/kg.
Missed dose: If therapy is interrupted longer than 7 days, resume at the lowest dose (e.g., 0.25 mg/kg) and increase gradually per prescriber and labeling. Do not double doses.
Before you give it — Safety check
Pretreatment checks
- Confirm life-threatening fungal indication, correct formulation (conventional vs liposomal), allergies, baseline creatinine/BUN, potassium, magnesium, and hepatic panel
- Review concurrent nephrotoxic drugs (aminoglycosides, cyclosporine, pentamidine) and corticosteroids/ACTH that may worsen hypokalemia
- Verify IV access, ordered premedication, hydration protocol, and independent double-check of mg/kg calculation (hard stop if > 1.5 mg/kg/day)
Contraindications
- Hypersensitivity to amphotericin B or formulation components—unless life-threatening infection with no alternative (per prescriber)
- Noninvasive fungal infections in patients with normal neutrophil counts (e.g., oral or vaginal candidiasis without systemic disease)
- Any planned daily dose above 1.5 mg/kg (contraindicated by labeling due to fatal overdose risk)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Other nephrotoxic drugs (aminoglycosides, cyclosporine, pentamidine) | Enhanced drug-induced renal toxicity | Use together only with great caution; intensive renal monitoring; report rising creatinine immediately |
| Corticosteroids / ACTH / digitalis glycosides | Amphotericin-induced hypokalemia may potentiate cardiac dysfunction and digitalis toxicity | Avoid concomitant corticosteroids unless necessary; monitor potassium and cardiac function closely; correct deficits promptly |
| Flucytosine / azole antifungals | Flucytosine toxicity may increase; some data suggest imidazoles may induce resistance to amphotericin B | Monitor for flucytosine toxicity; administer combination therapy with caution per infectious diseases and pharmacy |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Intravenous infusion only—under close observation by trained personnel
- Reconstitute with sterile water (no bacteriostatic agent), then dilute 1:50 in 5% dextrose to 0.1 mg/mL; do not use saline or other diluents
- Infuse slowly over approximately 2–6 hours; rapid infusion is associated with hypotension, hypokalemia, arrhythmias, and shock
- Use in-line filter with mean pore diameter not less than 1.0 micron; protect infusion from light; administer promptly after preparation
STOP and verify product name and dose if order exceeds 1.5 mg/kg—overdose may cause fatal cardiac or cardiopulmonary arrest. Extravasation causes chemical irritation; use appropriate peripheral or central access per protocol.
Expected therapeutic response
- Clinical stabilization or improvement of invasive fungal infection markers (fever curve, hemodynamics, source control) per infectious diseases assessment
- Microbiologic/clinical evidence of fungal clearance when follow-up cultures or imaging are ordered
- Tolerable infusion with manageable or diminishing infusion-related reactions after initial doses
Red flags — Stop and act
Amphotericin B carries boxed-level warnings for fatal overdose and serious infusion and renal toxicity. Stop the infusion and escalate when:
- Hypotension, bronchospasm, wheezing, cardiac arrhythmias, pulmonary edema, or cardiopulmonary arrest during or after infusion
- Rapidly rising creatinine/BUN, oliguria, anuria, or acute renal failure
- Symptomatic hypokalemia (muscle weakness, cramps) or ECG changes; potassium ≤ institutional critical value
- Anaphylactoid reaction, severe rash, or Stevens-Johnson syndrome/toxic epidermal necrolysis (post-marketing)
- Suspected overdose, wrong product, saline dilution, or infusion completed faster than ordered
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Fever, chills, malaise | Very common with infusion; worse with first doses | Premedicate per order; slow infusion; monitor vitals; differentiate from sepsis |
| Nausea, vomiting, anorexia | Common | Supportive care; alternate-day scheduling may reduce GI effects per labeling |
| Nephrotoxicity (azotemia, acute kidney injury) | Common; may be permanent with high cumulative dose or other nephrotoxins | Hold and notify when creatinine rises; maintain hydration; trend serum creatinine |
| Electrolyte wasting (hypokalemia, hypomagnesemia) | Common lab abnormalities | Monitor electrolyte panel; replace per order; watch for arrhythmias |
| Anemia, phlebitis/thrombophlebitis | Common/local | Monitor CBC; rotate/assess IV site; use scalp-vein needle or heparin per institutional protocol |
| Cardiopulmonary (hypotension, tachypnea, arrhythmias, shock) | Serious; rapid infusion increases risk | Never rush infusion; stop for hemodynamic instability; escalate urgently |
| Hypersensitivity, bronchospasm, anaphylaxis | Serious allergic reactions reported | Stop infusion; treat per protocol; never rechallenge after severe reaction |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Amphotericin B overdoses can result in potentially fatal cardiac or cardiopulmonary arrest. Under no circumstances should total daily dose exceed 1.5 mg/kg.
Management
- Discontinue therapy immediately and monitor cardiorespiratory, renal, hepatic, hematologic, and electrolyte status
- Provide supportive therapy as required; correct electrolyte deficiencies before reconsidering therapy
- Amphotericin B is not hemodialyzable; no specific antidote is listed in prescribing information
- Restart only after stabilization, beginning at the lowest dose (e.g., 0.25 mg/kg) and titrating gradually
Contact local poison control or medical toxicology services per facility protocol and local emergency guidance if overdose or preparation error is suspected.
Look-alike / sound-alike and error prevention
- Amphotericin B vs liposomal amphotericin B (AmBisome) — different mg/kg dosing and toxicity; verify vial label against MAR
- Amphotericin B vs amphotericin B lipid complex (Abelcet) / Amphotec — distinct products; never substitute without prescriber and pharmacy approval
- mg vs mg/kg — 50 mg vial does not equal a single 50 mg/kg dose; independent double-check required
- D5W vs normal saline — conventional product precipitates with saline; wrong diluent is a high-risk error
- Test dose omitted — first-exposure reactions are most severe; confirm test-dose orders completed
- Perform medication reconciliation to catch duplicate nephrotoxic antifungals or azoles
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Hydration | Some patients benefit from hydration and sodium repletion before doses to reduce nephrotoxicity—follow prescriber orders. |
| Premedication | Acetaminophen, antihistamines, antiemetics, or small-dose corticosteroids may be ordered per protocol; meperidine may shorten chills per labeling. |
| Infusion timing | Schedule IV infusion pump setup for 2–6 h duration; avoid rapid bolus. |
| Line care | Follow high-alert medication administration checks; assess site for phlebitis. |
| Lab cadence | Trend basic metabolic panel and liver function tests per prescriber; do not wait for symptoms alone. |
| Ask pharmacy when | Unclear formulation, compatibility, restart after hold, or precipitation in bag. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Pre-existing renal impairment | Frequent renal monitoring required; cumulative doses over 5 g or concurrent nephrotoxins increase risk of permanent impairment. Hydration and sodium repletion before doses may reduce nephrotoxicity per labeling. |
| Concurrent nephrotoxic or potassium-wasting therapy | Aminoglycosides, cyclosporine, pentamidine, diuretics, and corticosteroids require intensified renal and electrolyte surveillance. |
| Leukocyte transfusions / total body irradiation | Separate leukocyte transfusions from amphotericin B when possible; acute pulmonary toxicity reported. Leukoencephalopathy reported—irradiation may predispose. |
| Pregnancy | Pregnancy Category B in animal studies; human experience is limited but systemic fungal infections have been treated in pregnant patients without obvious fetal effects in small case series. Use during pregnancy only if clearly indicated. |
| Lactation | Not known whether excreted in human milk; because of potential toxicity, prudent to advise discontinuation of nursing during therapy per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Renal function (creatinine/BUN) frequently; use trends to guide dose changes
- Serum electrolytes—especially potassium and magnesium—plus liver function, CBC, and hemoglobin
- Vital signs and respiratory status during test dose and each infusion (infusion reactions 1–3 hours after start)
Document
- Product/formulation verified, mg/kg calculation, diluent (5% dextrose), infusion duration, filter used, and premedication given
- Infusion-related symptoms, intake/output, daily weights, and laboratory trends communicated to prescriber
- Hold events, nephrotoxic drug exposure, and patient education on chills/fever reporting
Patient teaching
- This medication treats serious fungal infection; report chills, fever, shortness of breath, chest tightness, or dizziness during infusion immediately
- You may receive medications before the infusion to reduce reactions—take them as ordered
- Report decreased urination, swelling, muscle weakness, cramps, or palpitations between doses
- IV therapy requires careful monitoring; do not miss scheduled labs
- Tell your team about all medicines and supplements—some increase kidney injury risk with this drug
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Ordered dose exceeds 1.5 mg/kg/day or suspected overdose
- Hypersensitivity/anaphylactoid reaction or hemodynamically significant infusion reaction
- Acute renal failure, rapidly rising creatinine, oliguria/anuria, or symptomatic electrolyte abnormalities pending prescriber review
- Wrong diluent (saline), visible precipitation, or infusion rate faster than ordered
- Leukocyte transfusion scheduled at the same time—coordinate timing per protocol
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Amphotericin B is often a last-line antifungal with unavoidable toxicity—nursing success is measured by safe infusion execution, early nephrotoxicity detection, and tight coordination with pharmacy and infectious diseases.
1. Check-before-you-give protocol
- Right patient, formulation, mg/kg (≤ 1.5 mg/kg/day), diluent (5% dextrose 0.1 mg/mL), and infusion time (≈2–6 hours)
- Baseline and most recent creatinine, potassium, magnesium; I&O and weight trend
- Premedication and hydration orders given; nephrotoxic MAR entries flagged
- Test-dose protocol completed when required with documented vitals
2. High-alert and safety badge
High-alert medication — verify dose & formulationFatal overdose risk above 1.5 mg/kg/day, complex preparation (dextrose only), and severe infusion/renal toxicity warrant independent double-checks and pharmacy involvement per institutional high-alert protocols.
3. Clinical workflow: hold and question rules
- If creatinine doubles or potassium falls with symptoms, hold, notify prescriber/pharmacist, and repeat BMP before restarting
- If infusion reaction includes hypotension or SpO2 drop, stop infusion, support ABCs, notify prescriber, document for premedication adjustment
- After interruption > 7 days, confirm restart at 0.25 mg/kg—do not resume full prior dose automatically
4. Critical teach-back questions
- “What symptoms during the infusion should you report right away?” (Patient should name chills, fever, trouble breathing, chest tightness, dizziness, or feeling faint.)
- “Why will you need frequent blood tests during this treatment?” (Patient should mention kidney function and potassium/magnesium monitoring to prevent serious complications.)
5. Care coordination
Pharmacist: Verify formulation-specific preparation, compatibility, premedication, and dose adjustments when creatinine rises
Infectious diseases / nephrology: Guide duration, combination therapy (e.g., flucytosine), and renal recovery plans when toxicity occurs
🧠 Quick mental checklist
- Is today’s mg/kg ≤ 1.5 and is this the correct formulation vial?
- Is diluent 5% dextrose to 0.1 mg/mL—not saline—and is infusion set for 2–6 hours?
- What did creatinine and potassium do since the last dose?
- Are any nephrotoxic drugs (aminoglycoside, cyclosporine) running concurrently?
- If chills or hypotension start, do I stop and escalate per protocol?
Amphotericin B NCLEX practice questions
This NCLEX-style clinical judgment practice set for amphotericin B uses a tabbed inpatient case (MAR, labs, I&O, nursing notes), then rotates priority action, cue recognition, renal/electrolyte trend interpretation, matrix urgency sorting, IV preparation judgment, and overdose management cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, I&O, and nursing note details for this case.
- Amphotericin B 50 mg vial — ordered 0.6 mg/kg IV daily (68 kg → 40.8 mg) in 500 mL D5W over 4 h
- Test dose 1 mg in 20 mL D5W over 30 min — due now, not yet given
- Gentamicin 5 mg/kg IV daily — scheduled 1800
- Acetaminophen 650 mg PO PRN chills — given 0700
- Hydrocortisone 50 mg IV premed — ordered 30 min pre-amphotericin B
- Admission: creatinine 1.0 mg/dL, BUN 18 mg/dL, K+ 4.0 mmol/L, Mg 1.9 mg/dL
- Day 3: creatinine 1.4 mg/dL, K+ 3.4 mmol/L
- Day 5 (today): creatinine 2.1 mg/dL, BUN 34 mg/dL, K+ 3.1 mmol/L, Mg 1.6 mg/dL
- AST 32 U/L, ALT 28 U/L, Hgb 9.8 g/dL
- IV fluids: 0.9% NaCl 1 L pre-dose (hydration protocol)
- Oral intake 720 mL
- Urine output 450 mL (down from 900 mL prior day)
- Weight +1.2 kg since admission
- 0700: Mild chills during prior infusion; BP remained 118/72; premeds given today
- 0900: Pharmacy flag — verify gentamicin + amphotericin B nephrotoxic combination
- 0930: Patient reports muscle cramps; nurse reviewing labs and I&O before test dose
Answer key & rationale
Frequently asked questions
Why must nurses track creatinine and potassium during amphotericin B therapy?
Prescribing information requires frequent renal function monitoring and regular serum electrolytes—especially magnesium and potassium—because nephrotoxicity, hypokalemia, and renal tubular acidosis are common. Lab trends should guide dose adjustments and hold decisions.
What infusion reactions should nurses expect with the first doses?
Fever, shaking chills, hypotension, nausea, vomiting, headache, and tachypnea commonly occur 1–3 hours after starting infusion and are usually more severe with the first few doses. Slow infusion over approximately 2–6 hours and test-dose monitoring help reduce risk.
When should a nurse hold amphotericin B and contact the prescriber or pharmacist?
Hold for suspected overdose (including any dose above 1.5 mg/kg/day), anaphylactoid or severe cardiopulmonary reactions, rapidly rising creatinine or anuria, symptomatic hypokalemia, unclear IV preparation, or orders to give with saline diluent instead of 5% dextrose per product labeling.
Can amphotericin B be mixed or infused with normal saline?
Conventional amphotericin B for injection must not be reconstituted with saline; the concentrate is further diluted in 5% dextrose injection to 0.1 mg/mL for infusion. Using other diluents or bacteriostatic agents may cause precipitation.
Is there an antidote for amphotericin B overdose?
No. Labeling states overdose can result in potentially fatal cardiac or cardiopulmonary arrest; discontinue therapy, provide supportive care, monitor cardiorespiratory and renal status, correct electrolytes, and stabilize before any restart at the lowest dose. Amphotericin B is not hemodialyzable.
References
-
U.S. National Library of Medicine. Amphotericin B for Injection USP — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a54943-9ce4-4f3e-b681-a1a9144c16ce
-
U.S. National Library of Medicine. AmBisome (amphotericin B liposome for injection) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9a38f63a-8852-6dab-e053-2a95a90a90d6
-
U.S. National Library of Medicine. AMPHOTEC (amphotericin B cholesteryl sulfate complex for injection) — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=9b8ea543-1de8-472f-9666-34f99ca2f183
-
National Center for Biotechnology Information, StatPearls. Amphotericin B. Bookshelf.https://www.ncbi.nlm.nih.gov/books/NBK482327/
-
U.S. Food and Drug Administration. AmBisome (amphotericin B liposome) label — clinical laboratory and nephrotoxicity definitions.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/050740Orig1s037Lbl.pdf
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.